BioSpace News Archive

Drug Development

MabVax CEO Looks for Potential Deals at JPM to Support its Human Antibody Programs

MabVax’s antibody-based radioimmunotherapy product MVT-1075 is currently being tested on 22 patients with CA19-9 positive malignancies in a Phase I trial.

January 9, 2018
·
3 min read
·
Alex Keown
Drug Development

FDA Slaps Breakthrough Tag on Eisai, Merck’s Combo Renal Cell Carcinoma Drug

The Phase II part of the trial is underway with patients who had select solid tumors with 0-2 prior lines of systemic therapy.

January 9, 2018
·
2 min read
·
Alex Keown
Policy

Parents Accuse Vtesse, Sucampo of Stealing Data From Their Sick Children

The suit, filed in Nevada Friday, comes after Vtesse was purchased by Sucampo for $200 million in April.

January 9, 2018
·
1 min read
Biotech Bay

3 Must-Buy Biotech Stocks for January

These prominent drug developers look to be enticing buys this month.

January 9, 2018
·
1 min read
Shenzhen’s HEC Pharm Invests in U.S. Novel Imaging Contrast Company

East Sunshine Foresight Fund will make a “series of investments” of unspecified size in Enlyton, a Columbus, Ohio company developing novel imaging contrast agents.

January 9, 2018
·
1 min read
Business

ICON Appoints Dr. James Cummings as President of ClinicalRM

Dr. Cummings has over 20 years’ experience within the global health and government research and development industries.

January 9, 2018
·
4 min read
Business

AbSci Appoints William F. Bennett, PhD to Scientific Advisory Board

A pioneer of the biotech industry, Dr. Bennett brings his decades of experience in downstream process development, protein purification, and regulatory affairs to the AbSci team.

January 9, 2018
·
2 min read
Business

ICON Issues Financial Guidance for Full Year 2018

For the full year 2018 revenue will be in the range of $1,870 - $1,930 million, representing growth of 7 - 10% and earnings per share will be in the range of $5.89 - $6.09, representing growth of 10 - 13%.

January 9, 2018
·
4 min read
Drug Development

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

The trial is enrolling patients with activating EGFR mutations across three settings.

January 9, 2018
·
8 min read
FDA

Xcision Wins FDA 510(k) OK for Breast Cancer GammaPod Stereotactic Radiotherapy System

With GammaPod, radiation oncologists will be at the forefront of a new era in cancer care by providing stereotactic radiotherapy treatments for the breast.

January 9, 2018
·
4 min read